ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Composite Inflammatory Indices for the Differentiation of Tuberculosis, Sarcoidosis, and Reactive Lymphadenopathy in Patients Undergoing EBUS-TBNA.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating mediastinal lymphadenopathy (LAP) due to tuberculosis, sarcoidosis, and reactive causes remains challenging because of overlapping clinical and radiological features. This study aimed to evaluate the diagnostic value of the systemic inflammation composite index (SICI), the platelet inflammation composite index (PICI), and other hematological indices for this differentiation.
methodsThis retrospective study included 223 patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal LAP between 2020 and 2025. Pre-procedural laboratory data were used to calculate the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and the newly defined SICI and PICI.
resultsPLR, NLR, SII, SICI, and PICI levels were highest in the tuberculosis group and were significantly higher in patients with granulomatous LAP than in those with reactive LAP (p < 0.001 for all). In differentiating tuberculosis from sarcoidosis, a SICI cut-off value of 10966.6 yielded a sensitivity of 83% and a specificity of 63%, while a PICI cut-off value of 2.2 yielded a sensitivity of 85% and a specificity of 60%. For distinguishing granulomatous from reactive LAP, the optimal cut-off values were 77.4 for PLR (sensitivity 98%, specificity 67%), 2721.5 for SICI (sensitivity 89%, specificity 63%), and 0.69 for PICI (sensitivity 87%, specificity 61%).
conclusionSICI and PICI, introduced for the first time in the literature, are readily available composite indices that may aid in differentiating tuberculosis-, sarcoidosis-, and reactive LAP-related mediastinal LAP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.